{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abrocitinib+100+mg", "query": { "intervention": "Abrocitinib 100 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abrocitinib+100+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T00:03:28.460Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04564755", "title": "Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "abrocitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-10-29", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Lancaster, California • Long Beach, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Lancaster", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04564755" }, { "nct_id": "NCT03915496", "title": "Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "PF-04965842 200 mg", "type": "DRUG" }, { "name": "PF-04965842 100 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-06-18", "completion_date": "2021-11-16", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 9, "location_summary": "Encinitas, California • Los Angeles, California • Largo, Florida + 5 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Largo", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03915496" }, { "nct_id": "NCT04345367", "title": "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Abrocitinib 200 mg", "type": "DRUG" }, { "name": "Dupilumab 300 mg", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 727, "start_date": "2020-06-11", "completion_date": "2021-07-13", "has_results": true, "last_update_posted_date": "2022-07-08", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04345367" }, { "nct_id": "NCT03796676", "title": "JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PF-04965842", "type": "DRUG" }, { "name": "PF04965842", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 287, "start_date": "2019-02-18", "completion_date": "2020-04-08", "has_results": true, "last_update_posted_date": "2022-04-13", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Madera", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Doral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03796676" }, { "nct_id": "NCT03720470", "title": "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis", "Dermatitis, Atopic", "Eczema", "Skin Diseases", "Skin Diseases, Genetic", "Genetic Diseases, Inborn", "Skin Diseases, Eczematous", "Hypersensitivity", "Hypersensitivity, Immediate", "Immune System Diseases" ], "interventions": [ { "name": "PF-04965842 100 mg", "type": "DRUG" }, { "name": "PF-04965842 200 mg", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" }, { "name": "Injectable Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 838, "start_date": "2018-10-29", "completion_date": "2020-03-06", "has_results": true, "last_update_posted_date": "2021-01-19", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03720470" }, { "nct_id": "NCT05743244", "title": "Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Abrocitinib 200 MG Oral Tablet", "type": "DRUG" }, { "name": "Ritlecitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "12 Years to 35 Years" }, "enrollment_count": 78, "start_date": "2023-10-19", "completion_date": "2027-10-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 23, "location_summary": "Orange, California • Palo Alto, California • San Francisco, California + 20 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743244" }, { "nct_id": "NCT05602207", "title": "Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Abrocitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovaderm Research Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-11-25", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Miami Lakes, Florida + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Quincy", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05602207" }, { "nct_id": "NCT02780167", "title": "Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "PF-04965842", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 269, "start_date": "2016-04", "completion_date": "2017-04", "has_results": true, "last_update_posted_date": "2019-05-02", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Encinitas, California • Pasadena, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Encinitas", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02780167" }, { "nct_id": "NCT03575871", "title": "Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "PF-04965842 100 mg", "type": "DRUG" }, { "name": "PF-04965842 200 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 391, "start_date": "2018-06-29", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 28, "location_summary": "Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575871" }, { "nct_id": "NCT01835197", "title": "First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-04965842", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 79, "start_date": "2013-05", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-06-20", "last_synced_at": "2026-09-27T00:03:28.460Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01835197" } ] }